12:00 AM
Dec 16, 2013
 |  BC Week In Review  |  Company News  |  Other News

Hologic diagnostic news

Hologic entered into a nomination and standstill deal with activist investor Carl Icahn. The company appointed Jonathan Christodoro and Samuel Merksamer, both managing directors at Icahn Capital L.P., as directors. Christodoro is also a director at Enzon Pharmaceuticals Inc. (NASDAQ:ENZN, Bridgewater, N.J.). Hologic's board now comprises 11 directors. As part...

Read the full 237 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >